Abstract
Neoadjuvant concurrent chemoradiotherapy with surgery is the standard treatment for esophageal squamous cell carcinoma (ESCC) in NCCN guidelines. But many patients refused or abandon radiotherapy because of the intolerable adverse effects. We designed a single-arm, open-label, phase II trial of pembrolizumab plus paclitaxel, cisplatin followed by Da Vinci robot surgery for locally advanced (stage III) ESCC. The purpose is to observe and evaluate the efficacy and safety.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have